Eliem Therapeutics Added to Russell 2000 and 3000 Indexes

SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 – Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced its inclusion in the Russell 2000® Index and the broader Russell 3000® Index, effective immediately. Dr. Aoife Brennan, CEO of Eliem Therapeutics, expressed the company's satisfaction, highlighting this milestone as a significant achievement for Eliem. The inclusion underscores Eliem's ongoing efforts in advancing scientific research and innovation, particularly with their promising CD19-targeted antibody, TNT119.

TNT119, a potent CD19-targeted antibody, has shown potential for various autoimmune diseases. Dr. Brennan emphasized that this inclusion in the Russell indexes aids in gaining broader market recognition and fosters further development of their innovative treatments. This move aligns with Eliem's strategic objectives to leverage their scientific advancements for treating conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.

The Russell 3000® Index, a comprehensive market-capitalization index, includes the 3,000 largest U.S.-traded stocks. Inclusion in this index automatically qualifies Eliem for the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, as well as the associated growth and value style indexes. These indexes are adjusted annually, ensuring that Eliem's inclusion remains effective for one year.

Russell indexes serve as critical benchmarks for investment managers and institutional investors, supporting index funds and active investment strategies. As of May 2024, assets totaling approximately $9.1 trillion are benchmarked against Russell's U.S. indexes, highlighting the significant role of these indexes in the financial sector. Provided by FTSE Russell, these indexes are part of a global indexing leader that offers comprehensive benchmarking, analytics, and data solutions to investors.

Eliem Therapeutics, Inc. is dedicated to developing therapeutics for autoimmune-driven inflammatory diseases. Their primary focus is on advancing TNT119, targeting a range of conditions including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Eliem's inclusion in the Russell indexes reflects their progress and commitment to pioneering treatments in the autoimmune disease space.

FTSE Russell, renowned for its benchmarking and data analytics expertise, underpins the indexes used by global investors. Their reliable and accurate indexes are essential tools for measuring and benchmarking market performance across various asset classes. FTSE Russell's adherence to high industry standards and transparent methodology is widely recognized, with their indexes being a preferred choice among institutional and retail investors for over three decades.

FTSE Russell is wholly owned by the London Stock Exchange Group, emphasizing its global reach and influence in the financial markets. The organization's commitment to innovation and client needs drives the continuous enhancement of its index offerings, supporting the dynamic requirements of the investment community.

In summary, Eliem Therapeutics' recent inclusion in the Russell 2000® and Russell 3000® indexes marks a pivotal step for the company. This achievement not only elevates Eliem's market profile but also reinforces their dedication to advancing therapeutic solutions for autoimmune diseases. As part of these prestigious indexes, Eliem is well-positioned to attract broader investor interest and continue its momentum in scientific innovation and market growth.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!